Shanghai, November 20, 2024 – The 12th edition of Analytica China, a premier trade fair for laboratory technology, analysis, biotechnology, and diagnostics in Asia, drew to a successful close at the Shanghai New International Expo Centre. The three-day event brought together over 1,200 domestic and international exhibitors, creating an efficient and professional platform for industry exchange.
During the exhibition, Cygnus Bio captured significant attention with its independently developed GS100 Sequencing System. The company showcased a range of application services based on the system, including genetic testing for medications related to the "four highs" (hypertension, hyperglycemia, hyperlipidemia, and hyperuricemia), cardiovascular and cerebrovascular drugs, combined risk assessment for hereditary early-onset coronary artery disease and Alzheimer's disease with individualized medication evaluation, as well as pharmacogenetic testing for psychiatric and neurological drugs. The Cygnus Bio team engaged in in-depth discussions with visitors, exploring the latest advancements and application scenarios of gene sequencing technology.
The GS100 Sequencing System leverages innovative one-step fluorogenic sequencing chemistry and error-correcting code (ECC) sequencing technology, delivering high accuracy, speed, and flexibility. More than ten application-oriented testing services developed on the S100 Sequencing System platform – featuring diverse sample collection methods and user-friendly operation – have garnered recognition and praise from partners and customers.
Looking ahead, Cygnus Bio will continue to drive innovation by optimizing its benchtop product series while introducing new sequencing system product lines designed for high-throughput, centralized clinical testing needs and more intelligent operation. The company aims to provide simpler, more precise, and efficient gene sequencing tools and solutions for life sciences research – including biology, medical diagnostics, drug development, animal and plant breeding, customs inspection, disease control, forensic science, and evolutionary studies – thereby offering robust technical support for both research and clinical applications. At the same time, Cygnus Bio will continue to expand and enrich its portfolio of application-oriented testing services to meet diverse customer needs, contributing technological strength to the improvement of public health.
